Rezolute to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Rezolute (Nasdaq: RZLT) announced management will participate in three investor conferences in late 2025: the Maxim Growth Summit on October 22-23, 2025, the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10-12, 2025, and the Jefferies London Healthcare Conference on November 17-20, 2025.

Management expects to hold one-on-one investor meetings during the events. Investors who want to schedule meetings are instructed to contact their Maxim, Guggenheim, or Jefferies representative.

Argus Oct 15 session

+6.89% close to close 0.8x rel. volume Open Argus

Details

News Market Reaction – RZLT

On Oct 15, the day this news came out, RZLT closed 6.89% above the previous close.

Data tracked by StockTitan Argus for the Oct 15 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:

Event: Maxim Growth Summit
Date: October 22-23, 2025

Event: Guggenheim 2nd Annual Healthcare Innovation Conference
Date: November 10-12, 2025

Event: Jefferies London Healthcare Conference
Date: November 17-20, 2025

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Maxim, Guggenheim, and Jefferies representatives.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.

Rezolute Contacts:

Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

Carrie McKim
cmckim@rezolutebio.com
336-608-9706

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which investor conferences will Rezolute (RZLT) attend in Oct–Nov 2025?

Rezolute will attend the Maxim Growth Summit (Oct 22-23, 2025), Guggenheim Healthcare Innovation Conference (Nov 10-12, 2025), and Jefferies London Healthcare Conference (Nov 17-20, 2025).

How can investors schedule a meeting with Rezolute management at the Maxim Growth Summit on Oct 22-23, 2025?

Investors should contact their Maxim representative to request a one-on-one meeting with Rezolute management.

How do I arrange a one-on-one meeting with Rezolute management at the Guggenheim conference on Nov 10-12, 2025?

Schedule meetings by contacting your Guggenheim representative as indicated by Rezolute.

Who should investors contact to meet Rezolute management at the Jefferies London Healthcare Conference on Nov 17-20, 2025?

Investors should contact their Jefferies representative to arrange a meeting with Rezolute management.

Will Rezolute (RZLT) hold one-on-one investor meetings during the listed conferences?

Yes. Rezolute management will be participating in one-on-one investor meetings throughout the conferences.

What is Rezolute's Nasdaq ticker and focus mentioned in the announcement dated Oct 15, 2025?

The company trades as RZLT on Nasdaq and is described as a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism.